Cipher Pharmaceuticals

219 articles with Cipher Pharmaceuticals

• Cipher Pharmaceuticals Receives Notice of Termination from Bausch

  1/20/2020

  Cipher Pharmaceuticals Inc. announced the Company received a Notice of Termination from Bausch Health in connection with the License, Development and Commercialization Agreement of Trulance®.

• Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

  11/7/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and nine months ended September 30, 2019. Unless otherwise noted, all figures are in U.S. dollars..

• Notice of Cipher Pharmaceuticals Q3 2019 Conference Call

  10/24/2019

  Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America.

• Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)

  10/18/2019

  Cipher Pharmaceuticals Inc. announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®, a Guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.

• Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

  8/9/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three months ended June 30, 2019.

• Notice of Cipher Pharmaceuticals Q2 2019 Conference Call

  7/30/2019

  Cipher Pharmaceuticals Inc. announced the details of its Q2 2019 financial results conference call on Friday, August 9, 2019.

• Cipher Pharmaceuticals Announces Management Change & Preliminary Q2 Financial Highlights

  7/29/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull has been named Interim Chief Executive Officer of Cipher, replacing Robert Tessarolo.

• Cipher Pharmaceuticals Reports Voting Results for the Election of Directors held on June 11, 2019

  6/12/2019

  Cipher Pharmaceuticals Inc., in accordance with Toronto Stock Exchange requirements, announced the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on June 11, 2019 in Toronto, Ontario.

• Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

  5/10/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31st, 2019.

• Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

  5/1/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Nadine Jutlah, Interim Chief Financial Officer.

• Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

  3/26/2019

  Cipher Pharmaceuticals Inc. today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately.

• Cipher Pharmaceuticals Announces Change to Management Team

  3/20/2019

  Cipher Pharmaceuticals Inc. announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities.

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

  3/19/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and twelve months ended December 31st, 2018.

• Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

  3/15/2019

  Cipher Pharmaceuticals Inc. announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019.

• Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

  12/18/2018

  Cipher Pharmaceuticals Inc. announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada.

• Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

  12/17/2018

  Cipher Pharmaceuticals (TSX:CPH) today  announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ("Synergy") in February 2018.

• Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

  12/5/2018

   Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET.

• Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

  12/4/2018

  Cipher Pharmaceuticals Inc. today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice President, Canadian Commercial Operations.

• Cipher Pharmaceuticals Reports Q3 2018 Results

  11/7/2018

  Canadian product revenue increased 27%

• 

  Synergy Pharma Struggles Despite Promising Market Opportunities in 2019

  10/26/2018

  After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.